Search our team at AdventHealth Research Institute
-
NCT06578247
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (QuANTUM-Wild)
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to learn more about an investigational drug called QUIZARTINIB. An investigational drug is a drug that is being studied to see if is safe, and to see if your disease or...
-
NCT06525220
MCLA-158-CL03: A phase III randomized, open label study to evaluate the efficacy and safety of Petosemtamab plus Pembrolizumab vs. Pembrolizumab in head and neck squamous cell carcinoma in the first line treatment of PD-L1+ (CPS?1) metastatic/recurrent disease without curative therapy available
This study is currently enrolling.Associated Conditions: Head and Neck CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purposes of this Study are to find out the possible side effects of the Study Drug, when used in combination with another, already approved, drug named pembrolizumab; if the Study Drug can or...
-
NCT05761171
AALL2121: A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe overall goal of this study is to determine the safety and best dose of the drug SNDX-5613 for young children when given in combination with chemotherapy, and to see if this treatment will improve...
-
NCT0645646
A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaOverall, the goal of this research study is to determine if tagraxofusp (Tag) in combination with venetoclax (Ven) and azacitidine (Aza) can safely treat cancer in patients who have not received...
-
NCT06401421
EXActDNA-003 Study (B-64/2023-05): Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThis study is evaluating a new type of biomarker found in individuals who have cancer. A biomarker is found in blood, other body fluids, or tissues related to traces of cancer remaining after cancer...
-
NCT06203600
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ? 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
This study is currently enrolling.Associated Conditions: Esophageal CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to answer the following questions: Can adding a drug to the usual treatment for advanced stomach and esophageal cancers make it less likely that these cancers will grow or...
-
NCT06457997
First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients with Advanced Solid Tumors
This study is currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe Sponsor will use tumor tissue samples along with other health information collected during the main study to conduct exploratory research in order to learn about the following: Why some people...
-
rhPSMA-7.3(18F)-PET scan to detect prostate cancer in patients with early PSA recurrence.
This study is currently enrolling.Associated Conditions: Prostate CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe research is being done at the Radiology Nuclear Medicine Department of AdventHealth Orlando and Celebration. Patients are instructed to drink water prior to administration of flotufolastat F-18 to...
-
NCT05858164
An open-label, phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics, and tumor response profile of the diacylglycerol kinase alpha inhibitor (DGKai) BAY 2862789 in participants with advanced solid tumors
This study is currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThis study is being done to learn more about a new drug called BAY 2862789, an inhibitor of diacylglycerol kinase alpha (DGKα). BAY 2862789 is an immunotherapy drug that has been developed to activate...
-
NCT05918913
SNDX-5613-0707: Expanded Access Program for SNDX-5613 in Patients with Relapsed/Refractory Acute Leukemias with Genetic Alterations Associated with HOXA Overexpression
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe therapy that will be receive involves being given the drug SNDX-5613 to treat Relapsed/Refractory acute leukemias, including those harboring an KMT2Ar Gene Rearrangement, Nucleophosmin 1 (NPM1m)...
-
NCT06226571
A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to find the best dose of revumenib taken with other cancer drugs, known as chemotherapy, and to find out what side effects happen after you take this study drug. It will...
-
NCT06384261
A multicenter, open label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy.
This study is currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to see if the investigational study drug, called cusatuzumab, is safe and effective when given together with other standard of care drugs used to treat Acute Myeloid...